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Background: Antibodies against spliceosome Sm proteins (anti-Sm autoantibodies) are specific to the autoimmune
disease systemic lupus erythematosus (SLE). Anti-Sm autosera have been reported to specifically recognize Sm D1
and D3 with symmetric di-methylarginines (sDMA). We investigated if anti-Sm sera from local SLE patients can
differentially recognize Sm proteins or any other proteins due to their methylation states.
Results: We prepared HeLa cell proteins at normal or hypomethylation states (treated with an indirect methyltransferase
inhibitor adenosine dialdehyde, AdOx). A few signals detected by the anti-Sm positive sera from typical SLE patients
decreased consistently in the immunoblots of hypomethylated cell extracts. The differentially detected signals by one
serum (Sm1) were pinpointed by two-dimensional electrophoresis and identified by mass spectrometry. Three identified
proteins: splicing factor, proline- and glutamine-rich (SFPQ), heterogeneous nuclear ribonucleoprotein D-like (hnRNP DL)
and cellular nucleic acid binding protein (CNBP) are known to contain methylarginines in their glycine and arginine rich
(GAR) sequences. We showed that recombinant hnRNP DL and CNBP expressed in Escherichia coli can be detected by all
anti-Sm positive sera we tested. As CNBP appeared to be differentially detected by the SLE sera in the pilot study,
differential recognition of arginine methylated CNBP protein by the anti-Sm positive sera were further examined.
Hypomethylated FLAG-CNBP protein immunopurified from AdOx-treated HeLa cells was less recognized by Sm1
compared to the CNBP protein expressed in untreated cells. Two of 20 other anti-Sm positive sera specifically
differentiated the FLAG-CNBP protein expressed in HeLa cells due to the methylation. We also observed deferential
recognition of methylated recombinant CNBP proteins expressed from E. coli by some of the autosera.
Conclusion: Our study showed that hnRNP DL and CNBP are novel antigens for SLE patients and the recognition of
CNBP might be differentiated dependent on the level of arginine methylation.
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A common feature of autoimmune diseases such as sys-
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reproduction in any medium, provided the orproteins [1]. Many autoantigens are post-translationally
modified. The modification might be induced by stresses
such as inflammation, apoptosis, and aging. Inefficient
clearance can lead to the presentation of the modified pro-
teins by antigen presenting cells as novel foreign proteins.
The possibility of posttranslational modification to create
new self antigens or mask antigens normally recognized
by the immune system has been proposed [2-4].
NG–monomethylarginine (MMA) and asymmetric NG,
NG–dimethylarginines (aDMA) are frequently identified
in various RNA binding proteins within the Arg Gly-GlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Chang et al. Journal of Biomedical Science 2013, 20:27 Page 2 of 10
http://www.jbiomedsci.com/content/20/1/27(RGG) context or Gly and Arg rich (GAR) region. The
methylation is catalyzed by the type I protein arginine
methyltransferase (PRMT) [5, 6]. Another type II PRMT
modifies other methyl-accepting proteins such as myelin
basic protein [7], core small nuclear ribonucleoprotein
(SnRNP) Sm B/B′, D1, D3 [8], and the Sm-like pro-
teins LSm4 [9] to form MMA and symmetric NG, N′G–
dimethylarginine (sDMA).
Interestingly, several autoantigens of different autoim-
mune diseases are type I or type II methyl-accepting pro-
teins. For example, fibrillarin (scleroderma) [10], hnRNP A1
(connective tissue diseases) [11], myelin basic protein (mul-
tiple sclerosis) [7], and SmD1 and D3 (SLE) [12] all contain
methylarginines. Furthermore, peptides with aDMA modi-
fication were identified as natural MHC class I ligands, in-
dicating that specific cytotoxic T-cell response against cells
presenting aDMA modified peptides can be elicited [13].
Anti-Sm antibodies are directed against the common
core proteins of U1, U2, U4 and U5 snRNP including
SmB/B′, D1, D2, D3, E, F, G, with B/B′, D1 and D3 most
frequently targeted. Anti-Sm antibodies are highly specific
to SLE and are found in up to 30% of the SLE patients
[14]. The direct link of arginine methylation and autoanti-
body recognition was shown by Brahms et al [8]. Ten of
eleven different anti-Sm autosera recognized the sDMA-
containing peptides of SmD1 and D3 but not un-
methylated or aDMA-containing peptides [8]. We thus
are interested in whether the anti-Sm sera from local SLE
patients also preferentially recognize the methyl-modified
Sm B/B′, D1 and D3 proteins, and if there might be other
proteins that can be differentially recognized by the anti-
Sm sera due to their methylation states. We treated HeLa
cells with adenosine dialdehyde (AdOx), an indirect
inhibitor of protein methylation, to accumulate hypo-
methylated proteins in cells. Among a few putative differ-
entially recognized proteins, three proteins containing
typical arginine and glycine (RG) sequences were identi-
fied. We showed that recombinant heterogeneous nuclear
ribonucleoprotein D-like (hnRNP DL) and cellular nucleic
acid binding protein (CNBP) expressed in Escherichia coli
can be detected by anti-Sm positive sera. We provided evi-
dences that arginine methylation of CNBP in the RG motif
is critical for the recognition of the protein by some of the
anti-Sm autosera.
Methods
Anti-Sm autosera from SLE patients
Anti-Sm autosera were collected from SLE patients from
Division of Rheumatology, Department of internal medi-
cine, Chung Shan Medical University Hospital, Taichung,
Taiwan. All patients were followed up at Chung Shan
Medical University Hospital and diagnosed using the 1982
revised criteria for SLE [15]. The presence of anti-Sm anti-
bodies was tested by double diffusion method of ENA-1kit (MBL, Nagoya, Japan) and direct antigen-specific
ELISA kit (INOVA Diagnostics Inc., San Diego, CA, USA)
as the manufacturer’s instructions. Most of the sera
showed speckled or nucleolar type for the antinuclear
antibody (ANA) test. The study was approved by the local
Institutional Research Board. Human normal control and
anti-Sm antibodies were purchased from INOVA Diag-
nostics (INOVA Diagnostics) and used as the control.
Cell cultures and protein extraction
HeLa cell culture, methylation inhibitor treatment (adeno-
sine dialdehyde, AdOx; Sigma-aldrich) and cell extract
preparation and SDS-polyacrylamide gel electrophoresis
(PAGE) were performed following the methods described
in [16]. To prepare HeLa cell extracts for two-dimensional
electrophoresis (2-DE), harvested cells were washed with
phosphate buffer saline (PBS) then resuspended in rehy-
dration buffer (8 M urea, 4% (w/v) CHAPS, 0.5% IPG buf-
fer pH3–10 or 4–7, 60 mM dithiothreitol, 0.002%
bromophenol blue). After 3-min shaking, cells were incu-
bated on ice for five minutes then centrifuged at 12,000×g
for 20 min at 4°C. Proteins in the extracts were quantified
by BCA kit (Pierce) or 2-D quant kit (GE-Amersham Bio-
sciences) with bovine serum albumin as the standard.
Two-dimensional gel electrophoresis
HeLa cell extract protein (250 μg) was applied to
immobilized pH gradient (IPG) strips (pH3–10 or 4–7,
7 cm) for isoelectrofocusing (IEF) electrophoresis. IEF
was carried out in an IPGphore system as instructed by
the manufacturer (GE Amersham Biosciences). Upon
completion of IEF (13,350 Volt-hours), the strips were
equilibrated and subjected to the second dimensional
SDS-PAGE as described [17]. The gels were stained
with coomassie brilliant blue or SyproRuby (Molecular
Probes).
Western blotting
Protein samples separated by SDS-PAGE or 2-D electro-
phoresis were transferred to nitrocellulose membranes.
The membranes were blocked in 5% skimmed dry milk
in TTBS (10 mM Tris-HCl, pH = 7.5; 100 mM NaCl;
0.1% tween 20) for 30 min, incubated with primary anti-
bodies (1:200 dilution for 7E6 antibody and 1:500 dilu-
tion for anti-CNBP from Abcam; 1:550 dilution for
SYM10, 1:900 dilution for SYM11 and 1:900 dilution for
ASYM24 from Upstate) at 4°C overnight, washed three
times in TTBS, then incubated with secondary antibody
(anti-mouse or rabbit IgG horse radish peroxidase conju-
gate from Sigma) for 1 h. Chemiluminescent detection
was performed using the Supersignal kit (Pierce) or
Western Blotting Luminol Reagent (Santa Cruz Biotech-
nology, Santa Cruz, CA) according to the manufacturer’s
instructions. If the first antibody is human serum, the
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dry milk in the blocking solution and antibody solution
will be increased to 7% and 0.7% respectively.Mass spectrometry
Desired protein spots were manually picked and in gel
digestion was performed using the Montage In Gel
Digsetzp Kit (Millipore) as described [17]. The trypsin-
digested peptides were then extracted, captured and
eluted. The eluted peptides were vacuum-dried and ana-
lyzed by Core Facilities for Proteomics Research in the
Institute of Biological Chemistry, Academia Sinica. Pro-
tein spots were subjected to concerted MALDI peptide
mass fingerprinting (PMF) and CID MS/MS analysis for
protein identification using a dedicated Q-Tof Ultima™
MALDI instrument (Micromass, Manchester, UK). The
instrument systems were operated under MassLynx 4.0
and raw MS data were processed for database searching
using ProteinLynx Global Server 2.0. For MALDI MS
and MS/MS analysis, samples were premixed 1:1 with
matrix solution (5 mg/ml CHCA in 50% acetonitrile,
0.1% v/v TFA and 2% w/v ammonium citrate). Within
each well, as many parent ions meeting the predefined
criteria (any peak within the m/z 800–3000 range with
intensity above 10 count ± include/exclude list) will be
selected for CID MS/MS using argon as collision gas and
a mass dependent ±5 V rolling collision energy until end
of probe pattern was reached, starting from the most in-
tense peak. The LM and HM resolution of theFigure 1 Differential recognition of proteins due to methylation statu
were prepared from cells grown in the presence or absence of 20 μM of A
onto nitrocellulose membrane. Western blot analysis was performed using
detected signals are indicated by arrows and the intensity ratios are shown
proteins are also indicated.quadrupole were both set at 10 to give a precursor selec-
tion window of about 4 Da wide.Protein identification
The MS or MS/MS spectra data were analyzed by Mas-
cot mass fingerprinting and MS/MS ion search (http://
www.matrixscience.com) with the following characte-
ristics: Peptide mass fingerprinting: Database: NCBInr;
Taxonomy: Homo sapiens; Enzyme: Trypsin; Fixed
modification: Carbamidomethyl (C); Variable modifica-
tions: Oxidation (M); Max missed cut: 1; Peptide toler-
ance: 50 ppm; Mass values: MH+. MS/MS ion search:
Da-tabase: NCBInr; Taxonomy: Homo sapiens; Enzyme:
Trypsin; Max missed cut: 1; fixed modification: Carba-
midomethyl (C); Variable modifications: Oxidation (M);
Peptide tolerance: 50 ppm; fragment mass tolerance:
0.25 Da; Peptide charge: 1+; Data format: Micromass
(.PKL); Instrument: MALDI-QUAD-TOF.Cloning of CNBP and plasmid constructs
cDNA clones of hnRNPDL and β-CNBP were obtained
from Source BIOScience LifeSciences (Berlin, Germany).
The coding region of hnRNP DL was amplified by poly-
merase chain reaction (PCR) with the hnRNP DL
forward (50-AAACCCGGGTATGGAGGATATGAACG
AG-30) and reverse (50-AAAAGCGGCCGCTTTAGT
ATGGCTGGTAA-3′) primers and subcloned into a TA
vector. The SmaI-NotI restriction fragment was sub-
cloned into the pGEX4T vector to prepare GST-fuseds by anti-Sm autosera. HeLa cell extracts (30 μg of total protein)
dOx. The cell extracts were separated by SDS-PAGE and transferred
Sm1, Sm2 and Sm3 autosera. The positions of the differentially
. The positions of typical anti-Sm recognized SmB/B′, SmD1 and D3
Figure 2 Resolving differentially recognized proteins by Sm1
autosera due to methylation status by 2-DE. HeLa cell extracts
(250 μg of total protein) treated with AdOx (lower panel) or not
(upper panel) were resolved by 2-DE, blotted and detected by
anti-Sm1. The other parallel gel was stained by SyproRuby. The
differentially detected signals that can match to protein spots are
indicated by red asteroid and numbered.
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with the CNBP forward primer (50-AAGGATCCATGA
GCAGCAATGAGT-30) and reverse primer (50-AAAA
GCGGCCGCAATTAGGCTGTAGCCTCA-30), and sub
cloned into a TA vector. The BamH1-EcoRI restriction
fragments were subcloned into the pGEX4T vector to
prepare GST-tagged CNBP. The CNBP coding sequenceamplified by the primer set ZNF9-Not-F (50-AAGCGGCC
GCCATGAGCAGCAATG-30) and ZNF9-BamH-R (50-
AGGATCCAATTAGGCTGTAGCCTCA-30) was cleaved
and the 50 NotI and 30BamHI restriction fragment was
subcloned into the pFLAG-CMV2 vector. The RG region
deletion was created by QuikChangeW II Site-Directed
Mutagenesis Kit (Stratagene) with the primers (Znf9-
DL1F: 50- CTACTGGTGGAGGCTTCCAGTTTGTTTC
C-30 and Znf9-DL1R:50- GAAACAAACTGGAAGCCTC
CACCAGTAGG-30) that contain the 33 bp deletion. The
CNBP coding sequence was subcloned into pET28b by
PCR amplification and BamHI-SalI restriction digestion.
Purification of recombinant proteins expressed in E. coli
Expression of GST-CNBP or GST-hnRNP DL fusion pro-
teins in Escherichia coli DH5αor BL21 (DE3) cells was
induced with IPTG and purified using Glutathione Sephar-
ose affinity chromatography (GE Amersham Biosciences)
according to the manufacturer’s instructions. (His)6-tagged
CNBP protein was prepared from E. coli cells transformed
with pET-28b-CNBP. The pellet of the extract containing
(His)6-fusion proteins was resuspended with 3 ml Buffer A
(6 M Guanidine-HCL, 0.1 M NaH2PO4, 0.01 M Tris-HCL,
0.1 M β-mercaptoethanol, 0.01 M PMSF, pH 8.0) at room
temperature for 1 hr, followed by centrifugation at
10000 × g for 10 min. The supernatant was loaded to a Ni-
NTA agarose column (Qiagen). Bound (His)6-CNBP fusion
proteins were washed and eluted according to the sugges-
tions of the manufacturer. To prepare methylated CNBP,
pET-28b-CNBP and pGEX-PRMT1 were co-transformed
into BL21 (DE3) cells and selected with both ampicillin
and kanamycin.
Transfection and purification of FLAG-CNBP
For transfection, HeLa cells were transfected with
pFLAG-CNBP plasmid using Lipofectamine (Invitrogen,
Camarillo, CA). AdOx (20 μM) was included in the
MEM medium 24 hr after transfection, and the cells
were cultured for another 24 hr. HeLa cell extracts prep-
aration and immunopurification of FLAG-CNBP protein
were conducted as described [18].
Results
Proteins other than Sm proteins were differentially
recognized by local SLE anti-Sm positive autosera due to
their methylation status
We first examined whether the anti-Sm positive autosera
from local SLE patients can differentially recognize Sm
proteins or certain other proteins due to their methylation
status. We prepared hypomethylated cell extracts from
HeLa cells treated with the methyltransferase inhibitor
AdOx. Reduced protein arginine methylation under the
condition has been determined previously [8] and was ex-
amined for different batches of extracts prepared in this
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*x indicates that the PMF search results were not consistent with the MS/MS results. “None” indicates that none of the PMF (peptide mass fingerprint) results
(protein scores) are significant. The protein score in parentheses is not significant.
Figure 3 The amino acid sequence of human CNBP. The seven
Cys-Cys-His-Cys (CCHC) type zinc knuckle domains (C-Φ-X-C-G-X3-H-
X4-C, where Φis an aromatic amino acid and X is a variable amino
acid) in the human CNBP protein are underlined. The RG sequence
between zinc finger ZF1 and ZF2 is indicated with shading. The
peptide sequence identified by MS/MS is boxed.
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anti-Sm positive sera (Sm1, 2 and 3) from three typical
SLE patients for immunoblot analyses. The overall detec-
tion patterns by the same serum were similar whether the
proteins were from AdOx-treated or untreated HeLa cells.
Signals correspond to SmB/B′ and Sm D1/D3 were
detected clearly but without differential recognition. Never-
theless, reduced signals between molecular mass of 18 to
23 kDa were consistently detected by Sm1, 2 and 3 in the
hypomethylation samples (Figure 1). The Sm1 serum
appeared to differentially recognize more polypeptides at
the molecular mass of about 36, 40 and 49 kDa.
To obtain better resolution of the putative methy-
larginine-dependent recognition targets of Sm1, we
conducted two-dimensional electrophoresis (2-DE) to
separate the HeLa cell proteins. Specific spots were
strongly recognized by Sm1 from cell extracts with no
AdOx treatment but not the extracts treated with AdOx
(Figure 2). The spots were of similar molecular masses
as those detected by one-dimensional SDS-PAGE. The
differentially recognized spots by Sm1 in the immuno-
blots were compared with the protein spots of a parallel
coomassie-stained 2-DE gel. The matched protein spots
were digested with trypsin and subjected to mass spec-
trometry. Through proteomic analyses, seven putative
differentially recognized spots by Sm1 were identified as
eight different proteins. The identified polypeptides arelisted in Table 1. For spot 1, 2 and 3, two different poly-
peptides were identified for the same spot. α-enolase (or
called non-neuronal enolase) was identified for spot 2, 3,
and 4 in a row with similar molecular masses but different
isoelectric points (pIs). The unambiguous identification of
a polypeptide should be supported by at least one peptide
with a Mascot ion score higher than the number that indi-
cates identity.Identification of known methylarginine containing
proteins as the differentially recognized proteins
Three of the identified target proteins: splicing factor,
proline- and glutamine-rich (SFPQ), heterogeneous nu-
clear ribonucleoprotein D-like (hnRNP DL or JKTBP1)
and cellular nucleic acid-binding protein (CNBP), contain
Table 2 Summery of the detection of recombinant hnRNP
DL /CNBP and differential recognition of methylated
CNBP protein by the anti-Sm positive sera from SLE














X1 + + + − +
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methylation. Arginine methylation of RNA binding pro-
teins SFPQ and hnRNP D-like was reported by Ong et al.
[19] and Uhlmann et al. [20] in proteomic screening of
methylarginine containing proteins. A peptide (FGQG
GAGPVGGQGPR) with a significant ion score of 54
(higher than 43 indicate identity) unambiguously identi-
fied the protein SFPQ in spot 2. However, this spot
appeared to contain protein α-enolase also. The theoret-
ical molecular weight and pI value of α-enolase is close to
the experimental ones while the theoretical values of
SFPQ are very different from the experimental ones. It is
thus likely that the spot contained degradation products
or small isoforms of SFPQ.
An RNA binding protein hnRNP DL with high sequence
similarity with hnRNP D (AUF1) and hnRNP A1 shuttles
between nucleus and cytoplasm [21]. Anti-hnRNP A1 has
been reported in autoimmune diseases including RA, SLE
and MCTD as reviewed [22]. Anti-hnRNP D antibodies
were detected in SLE and RA patients [23]. However,
autoantibody to hnRNP DL has not been reported.
Another polypeptide of molecular mass about 19 kDa
and pI 7.9 was identified by mascot search of the MS/MS
data. A peptide (GFQFVSSSLPDICYR + carbamidome-
thyl) with significant mascot score 62 (scores greater than
39 indicate identity) identified the cellular nuclear acid
binding protein (CNBP or ZNF9). CNBP contains seven
tandem Cys-Cys-His-Cys (CCHC) type zinc knuckle do-
mains and typical arginine and glycine (RG) sequences be-
tween the first and the second zinc buckle (Figure 3).
CNBP was identified as a putative symmetric dime-
thylarginine containing protein in an immunopurification
study with a symmetric dimethylarginine specific anti-
body SYM10 for methylarginine protein complexes [24].
Methylation at the arginine residues in the RG region
of a specific splicing isoform was recently reported by
Uhlmann et al. [20].X7 + − + − −
X8 + + + − −
X9 + + + − −
X10 + − + − −
X11 + + + − ±
X12 + + + − +
X13 + − ± − −
X14 + − ± − −
X15 + + + − −
X16 + − + − −
X17 + + + − ±
X18 + + + + ±
X19 + − + − +
X20 + + ND − NDRecognition of hnRNP DL and CNBP by other anti-Sm
positive patient sera
We are interested in whether the RGG or GAR-con-
taining proteins identified in this study are the targets for
more SLE patients. We prepared recombinant GST-fused
hnRNP DL and CNBP protein expressed in Escherichia
coli. Besides the sera used in the pilot study, we included
twenty anti-Sm positive sera from local SLE patients. De-
tections of the two putative autoantigens were summa-
rized in Table 2. All of the sera can detect GST-tagged
hnRNP DL and 60% (12/20) of the sera can detect CNBP
by immunoblots. None of the sera can detect GST protein
alone at the same protein amount. Part of the immuno-
blotting results were shown in Figure 4. Normal control
sera pooled from individuals without autoimmunitymarginally recognized the protein upon longer exposure
(data not shown).
We further prepared recombinant (His)6-CNBP fusion
proteins from E. coli cells and then screened Sm-positive
sera for their recognition of recombinant CNBP. Basically,
all of the sera examined, even the ones that did not detect
GST-tagged CNBP, recognized (His)6-tagged CNBP. The
results were listed in Table 2.
Anti-nuclear antibody (ANA) is critical for the diagnosis
of SLE patients. We determined the ANA pattern of
CNBP using a commercially available goat anti-CNBP
antibody. Predominant nuclear positive staining was
detected on standard HEp-2 cells at 100× dilution for the
ANA test (data not shown) and similar nuclear expres-
sion pattern of CNBP was also detected in HeLa cells
(Wei et al., manuscript in preparation).
Confirmation of the differential recognition of CNBP by
Sm1 autosera due to arginine methylation
As the signal corresponding to CNBP was likely to be dif-
ferentially recognized by Sm1, 2, and 3, we determined to
confirm whether protein arginine methylation of CNBP is
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of the CNBP spots of AdOx-treated or untreated cell ex-
tracts in the 2-DE gels were of similar level, suggesting
that the differential recognition was not due to reduced
level of CNBP protein (data not shown), and thus was
more likely to be due to the reduced methylation level of
CNBP in the AdOx-treated samples.
We then prepared immunopurified FLAG-CNBP protein
from transfected HeLa cells cultured in the presence or ab-
sence of AdOx. Sm1 detected FLAG-CNBP from un-
treated HeLa cells to a much higher extent than that from
AdOx-treated cells (Figure 5). The same membrane was
re-probed with a methylarginine-specific antibody 7E6.
7E6 clearly detected the FLAG-CNBP protein prepared
from HeLa cells without AdOx treatment but not the
CNBP protein from AdOx-treated cells (Figure 5). The re-
sults indicated that the CNBP protein is arginine methyl-
ated and the methylation level of the protein can be
reduced by AdOx treatment. Re-probing of the membrane
with anti-FLAG antibody showed equal loading, indicating
the reduced FLAG-CNBP signal of the AdOx treated sam-
ples detected by Sm1 was not due to reduced protein level
in the sample. Overall the experiments indicated that theFigure 4 Recognition of hnRNP DL and CNBP by anti-Sm positive SLE
described in Methods. The GST-fused proteins or GST were applied to SDS
(pt) 2 and 18 are shown.recognition of CNBP by the specific SLE autosera Sm1 re-
lies on arginine methylation.Differential recognition of CNBP by other anti-Sm
positive patient sera
To examine whether the autoantibodies that can differen-
tially recognize arginine methylated CNBP are present in
other SLE patients, we then screened anti-Sm positive SLE
patient sera for their recognition of arginine methylated
CNBP. Since protein arginine methylation is rather stable,
inhibition of the modification by AdOx treatment appears
to be most effective for newly synthesized polypeptides
[18]. Compared to other endogenous HeLa cell proteins
that might have been synthesized before transfection and
AdOx treatment, the transiently expressed FLAG-CNBP
protein showed significant decrease of arginine methyla-
tion level upon AdOx treatment (Figure 6A). We thus
used cell extracts from FLAG-CNBP transfected and
AdOx treated HeLa cell extracts to screen the autosera.
As for Sm1-3, we did not detect differential recognition of
SmB/B′, D1 and D3 proteins by all of these patient sera.
We cannot exclude the possibility that the recognition ofpatient sera. GST-fused hnRNP DL and CNBP were prepared as
-PAGE and the immunoblots detected by the autosera from patient
Figure 5 CNBP is methylated in vivo and is recognized
differentially by Sm1 due to its methylation status. HeLa cells
were transfected with pFLAG-CNBP plasmids. The FLAG-tagged proteins
were immunoprecipitated by anti-FLAG agarose. Proteins eluted by the
FLAG peptide were then analyzed by Western blot analyses with anti-
Sm1. The blot was stripped of the interacted antibodies and then
probed with a mono- and di-methylarginine-specific antibody 7E6. The
same blot was stripped and then re-probed with the anti-FLAG antibody.
The internal blank region of the FLAG-CNBP signal of the AdOx- sample
detected by anti-FLAG was due to previous stripping.
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tion by the anti-Sm antibodies. However, among the
twenty Sm-positive SLE patient sera, two (patient 5 and
18) showed methylation differential recognition of CNBP.
The results were outlined in Table 2. On the contrary, the
pooled normal control sera did not detect the signal (data
not shown).
Furthermore, we prepared arginine-methylated recom-
binant (His)6-CNBP fusion proteins from E. coli cells by
co-transformation with plasmids expressing GST-PRMT1.
We then screened Sm-positive sera for their recognition
of the recombinant CNBP. We also observed deferential
recognition of PRMT1-methylated CNBP by some of the
autosera including Sm1 (Figure 6B). The results were
summarized in Table 2. There were some discrepancies
between the differential recognition of the methylated
CNBP that were FLAG-tagged and expressed in HeLa
cells or the (His)6-tagged CNBP expressed in E. coli.
Discussions
Many methylarginine-containing proteins such as fib-
rillarin [10], hnRNPA1 [25] and Sm proteins [8] are
autoantigens. However, the only direct link between pro-
tein arginine methylation and autoantibody recognition isthe report by Brahms et al. that symmetric dime-
thylarginines in SmD1 and D3 are responsible for the ma-
jority of the anti-Sm recognition of the SLE patient sera
[8]. In this study, we examined whether the anti-Sm-posi-
tive autosera from local SLE patients can differentially
recognize the Sm proteins due to their methylation status.
We did not detect differential recognition of the SmD1,
D3 or B/B′ proteins under our experimental conditions
(HeLa cells treated with the methylation inhibitor AdOx
or not). Immunoblotting with an sDMA-specific antibody
showed reduced symmetric dimethylation of SmB/B′ and
SmD proteins upon AdOx treatment (data not shown),
confirming that our treatment can effectively decrease
protein arginine methylation. Nevertheless, differential
recognition in other proteins was detected by the anti-Sm
serum from typical SLE patients.
In our pilot study through proteomic analyses, we iden-
tified eight different proteins from seven putative differen-
tially recognized spots with the Sm1 sera from a typical
SLE patient. Three metabolic enzymes without known or
predicted protein arginine methylation sites were identi-
fied. Among these, antibodies against α-enolase have been
detected in many infectious and autoimmune diseases in-
cluding SLE. The frequency of SLE patients with α-enolase
Abs was around 20% and increased to about 60–80% for
SLE with active renal disease [26]. Succinyl-CoA:3-ketoacid
coenzyme A transferase 1 and aldehyde dehydrogenase X
were both identified for spot 1. These two proteins have
not been reported to be targets of autoantibodies. Two
other proteins, putative beta-actin-like protein 3 along with
LIM and SH3 domain protein 1, contain no known or pre-
dicted protein arginine methylation sites and have not been
reported to be autoantigens.
Three proteins SFPQ, hnRNPDL and CNBP contain RG
or RGG repeats typical for PRMT-modified arginine
methylation [19, 20] were identified by proteomic analyses
as putative candidate protein that can be differentially rec-
ognized by SLE. Splicing factors such as various SR pro-
teins have been reported as autoantigens of SLE [27]. No
report has suggested SFPQ as an autoantibody target.
hnRNP DL shares high sequence similarity with hnRNPD
(AUF1) and hnRNPA1. Anti-hnRNP A1 has been reported
in autoimmune diseases including RA, SLE and MCTD as
reviewed [22]. Anti-hnRNP D antibodies were detected in
SLE and RA patients [23]. However, autoantibody to
hnRNP DL has not been reported. In this study we
showed that all of the anti-Sm positive sera from local SLE
patients recognized recombinant hnRNPDL, indicating it
to be a novel autoantigen.
The CNBP gene has been related to the human disease
myotonic dystrophy type 2 (DM2) for the expansion of
CCGC repeats in intron 1 [28]. CNBP has not been
reported to be the target of autoantibodies. It is known to
regulate the translation of ribosomal protein mRNA
Figure 6 Differential detection of CNBP protein by anti-Sm positive SLE sera. (A) HeLa cell extracts prepared from cells that were
transfected with the pFLAG-CNBP plasmid and treated with AdOx or not were analyzed by Western blot analyses with an aDMA-specific antibody
ASYM24 (left panel) or autosera from SLE patient 18 (right panel) and re-probed with anti-FLAG antibodies. The positions of FLAG-CNBP are
indicated by arrows. (B) (His)6-CNBP proteins prepared from E. coli cells co-expressing PRMT1(M-CNBP) or not (CNBP) were analyzed by Western
blot analyses. Differential detection of (His)6-CNBP by autosera from patient 5, 18 and Sm1 are shown. Arginine methylation of CNBP was
confirmed by the detection with ASYM24. The blot was stripped and re-probed with anti-(His)6 (His-tag) antibodies.
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sequence in the 50-UTR. Interestingly, two typical SLE
autoantigens La and Ro are involved in the TOP-mRNA
regulation. Both CNBP and La can bind to the 50-TOP
and their binding is mutually exclusive. They compete for
the interacting protein Ro that is the common factor ne-
cessary for the binding of La or CNBP proteins [29]. As
proteins in a similar functional complex/pathway appears
to be processed and presented for antibody formation in
autoimmune patients, whether CNBP is an autoantigen is
an interesting issue.
We analyzed sera from anti-Sm positive patients and
more than 60% can detect recombinant GST-CNBP pro-
tein expressed by E. coli. When we further prepared
(His)6-tagged CNBP, all of the autosera we tested
recognize the protein. CNBP thus appear to be a novel
autoantigen recognized by the Sm-positive SLE patients.
We focused on the demonstration of the differential
recognition of CNBP due to its methylation status. We
prepared FLAG-tagged CNBP protein expressed in AdOx-
treated HeLa cells. FLAG-CNBP from AdOx-treated cells
was less recognized by Sm1 autosera compared to the
CNBP protein expressed in untreated cells. The results
confirmed that CNBP is methylated and the methylation
facilitates the recognition of Sm1. However, the differential
recognition of CNBP due to its methylation status is re-
stricted to few anti-Sm positive SLE patient sera.Furthermore, as shown in Table 2, the differential recogni-
tion detected using the methylated (His)6-tagged CNBP
expressed in E. coli were slightly different from the FLAG-
tagged CNBP expressed in HeLa cells. For example, Sm1
significantly discriminate FLAG-CNBP expressed in HeLa
cells treated with AdOx or not, but barely differentially
recognize PRMT1-methylated or unmethylated (His)6-
CNBP. As AdOx treatment inhibits all type of methylation
but PRMT1 only catalyzes the formation of aDMA, the
difference might be due to sDMA. In fact, FLAG-CNBP
immunopurified from HeLa cell extracts could be detected
by aDMA as well as sDMA-specific antibodies (Hu et al.,
unpublished results). The results raised the possibility that
some patient sera might distinguish sDMA but others
aDMA-modified CNBP.
Conclusions
In conclusion, through proteomic analyses, a few putative
differentially recognized proteins were identified. Among
them three proteins contain arginine methylation sites
were identified by proteomic analyses. We showed that a
portion of SLE patients who have anti-Sm autoantibodies
can specifically recognize specific methylarginine contai-
ning proteins. Our study showed that hnRNP DL and
CNBP are novel antigens for SLE patients and the recog-
nition of CNBP might be differentiated dependent on the
level of arginine methylation.
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